


41

AF 11632  
RECEIVED



# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

DEC 12 2003

TECH CENTER 1600/2900

PARKER  
PARTNER  
DPARKER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3055  
TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

December 3, 2003

| CERTIFICATE OF MAILING<br>37 C.F.R. 1.8   |                                       |
|---|---------------------------------------|
| I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria VA 22313-1450, on the date below: |                                       |
| <u>December 3, 2003</u><br>Date   | <u>[Signature]</u><br>David L. Parker |

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Re: SN 09/351,778 entitled "Replication Competent Anti-Cancer Vectors"  
by Wold et al.  
Our ref: INGN:109US

Commissioner:

Enclosed for filing in the above-referenced patent application are the following:

- (1) Amendment and Response to Office Action Dated September 3, 2003;
- (2) Supplemental Declaration of the Inventors Under 37 C.F.R. §1.131; and
- (3) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/INGN:109US

Very truly yours,

[Signature]  
David L. Parker  
Reg. No. 32,165

DLP/lb  
Enclosures

25363111.1